现代检验医学杂志2024，Vol.39Issue(1)：83-89,7.DOI:10.3969/j.issn.1671-7414.2024.01.015
肝细胞肝癌患者血清LG2m和hPG80表达水平及临床价值研究
Study on the Expression Levels and Clinical Value of Serum LG2m and hPG80 in Patients with Hepatocellular Carcinoma
摘要
Abstract
Objective To study the serum laminin γ 2 monomer(LG2m),human circulating Gastrin(hPG80)in patients with hepatocellular carcinoma(HCC)and their clinical value.Methods 128 HCC patients admitted to the First People's Hospital of Shuangliu District from January 2016 to January 2018 were selected as the HCC group,70 patients with benign liver lesions diagnosed and treated at the same time were selected as the benign lesion group,and 70 healthy individuals who underwent physical examinations during the same time were selected as the control group.Use enzyme-linked immunosorbent assay to detect serum LG2m and hPG80 levels.The evaluation value of serum LG2m and hPG80 in predicting the prognosis of HCC patients were analyzed by receiver operating characteristic curve.Kaplan-Meier survival analysis was used to compare the survival prognosis of HCC patients with different serum LG2m and hPG80 levels.COX regression analysis was used to analyze the prognostic factors of HCC patients.Results The levels of serum LG2m(28.14±3.10 ng/L),hPG80(84.83±11.39 ng/L)in the HCC group were higher than those in the benign lesion group(9.18±1.74 ng/L,25.10±4.11 ng/L)and the control group(8.24±1.65 ng/L,23.15±3.26 ng/L),and the differences were statistically significant(t=68.240～76.635,all P＜0.05).The levels of serum LG2m and hPG80 in patients with TNM stage III,low differentiation degree,serum AFP＞400 μg/L were higher than those in TNM stage I to II,high differentiation,AFP≤400 μg/L,the differences were statistically significant(t=3.216～13.552,all P＜0.05).The area under the curve(95%CI)of the combined evaluation of serum LG2m and hPG80 for the prognosis of HCC patients was 0.934(0.889～0.961),which was greater than the single indicator of 0.813(0.774～0.849)and 0.896(0.840～0.937).The overall 5-year survival rates of HCC patients with high and low serum LG2m expression were 33.33%(21/63)and 67.69%(44/65),respectively.Compared with HCC patients with low expression of serum LG2m,HCC patients with high expression of serum LG2m had a lower 5-year cumulative survival rate(Log-Rankχ2=19.522,P＜0.05).The overall 5-year survival rates of HCC patients with high and low serum hPG80 expression were 35.48%(22/62)and 65.15%(43/66),respectively.Compared with HCC patients with low serum hPG80 expression,HCC patients with high serum hPG80 expression had a lower 5-year cumulative survival rate(Log-Rankχ2=12.546,P＜0.05).TNM stage III(OR=1.487,P＜0.05),low differentiation degree(OR=1.611,P＜0.05),serum AFP≥400μg/L(OR=1.416,P＜0.05),high expression of serum LG2m(OR=1.838,P＜0.05),and high expression of hPG80(OR=1.735,P＜0.05)were independent risk factors for poor prognosis in HCC patients.Conclusion The serum levels of LG2m and hPG80 in HCC patients increase,which are related to TNM staging,tumor differentiation,and serum AFP levels.They are serum biomarkers for evaluating the survival and prognosis of HCC patients.关键词
肝细胞肝癌/层黏连蛋白γ2单体/人循环前胃泌素Key words
hepatocellular carcinoma/laminin gamma 2 monomer/human circulating gastrin分类
医药卫生引用本文复制引用
刘宏,张春华,阳宏,王万琴..肝细胞肝癌患者血清LG2m和hPG80表达水平及临床价值研究[J].现代检验医学杂志,2024,39(1):83-89,7.基金项目
四川省医学卫生健康科研课题(19PJ065):肝细胞肝癌(HCC)患者血清LG2m,hPG80的水平及临床意义. （19PJ065）
